Insulet Corporation revised earnings guidance for the year ending December 31, 2024. For the year ending December 31, 2024, the company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
182.2 USD | +2.84% | +2.56% | -15.95% |
May. 30 | Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target | MT |
May. 29 | Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.95% | 12.41B | |
-6.39% | 178B | |
-0.24% | 107B | |
-2.16% | 67.04B | |
-7.49% | 47.23B | |
+11.68% | 44.62B | |
+9.25% | 42.5B | |
+15.51% | 29.99B | |
+15.97% | 25.22B | |
-6.99% | 24.14B |
- Stock Market
- Equities
- PODD Stock
- News Insulet Corporation
- Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024